Sign inJoin waitlistJoin the waitlist

PI

Prioty Islam

Clinical Director, Leukemia Service · New York Presbyterian Hospital

Credentials: · · · · · ·

History

Leukemia Service · New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Duke University Hospital
2018–2021
Internal Medicine
Emory University
2015–2018
Perelman School of Medicine at the University of Pennsylvania
2011–2015

Research

PET-derived tumor metrics predict DLBCL response and progression-free survival
Leukemia & lymphoma/Leukemia and lymphoma · 2019 · First of 3 authors · 26 citations
Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation
Transplantation and Cellular Therapy · 2021 · First of 15 authors · 13 citations
Utilizing Real-World Evidence (RWE) to Improve Care in Chronic Lymphocytic Leukemia: Challenges and Opportunities
Review · Current Hematologic Malignancy Reports · 2020 · First of 2 authors · Corresponding · 13 citations

Lindsey Roeker
6 papers · 1 as a fellow
Anthony Mato
5 papers
Alan Skarbnik
4 papers
Danielle Brander
4 papers
Meghan Thompson
4 papers
David Rizzieri
3 papers
Jennifer Woyach
3 papers
Joanna Rhodes
3 papers
John Allan
3 papers
Mazyar Shadman
3 papers
Mitchell Horwitz
3 papers
Seema Bhat
3 papers

Clinical trials

A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2026–2032
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2032
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Site PI · Recruiting · Phase 1, Phase 2
Disc Medicine, Inc
2022–2027